Apexigen's Shares Fall After Data From Gastric Cancer Candidate

  • Apexigen Inc APGN announced the presentation of new data from a Phase 2 trial evaluating sotigalimab (sotiga) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers. 
  • Sotiga combined with neoadjuvant chemoradiation for esophageal/GEJ cancers was generally safe and well tolerated.
  • Most patients had Grade 1-2 adverse events (AEs).
  • There were no patient withdrawals due to sotiga and no sotiga/neoadjuvant chemoradiation-related deaths.
  • Encouraging pathologic complete response (pCR) rates were observed in patients with both adenocarcinoma (AC) and squamous cell carcinoma (SCC).
  • Of the 29 evaluable patients, 11 (38%) patients had a pCR, and 19 (66%) patients had an mPR (significant pathological response) with less than 10% of the residual tumor remaining after treatment.
  • The pCR rate was 41.2% for patients (n= 17) receiving four doses of sotiga versus 33.3% for patients (n= 12) receiving three doses.
  • R0 resection was achieved in 86% (25/29) patients, and progressive disease was only 7%.
  • Price Action: APGN shares are down 8.02% at $7.00 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!